ImmunityBio
IBRX
386 hedge funds and large institutions have $1.36B invested in ImmunityBio in 2026 Q1 according to their latest regulatory filings, with 145 funds opening new positions, 136 increasing their positions, 60 reducing their positions, and 30 closing their positions.
383% more first-time investments, than exits
New positions opened: 145 | Existing positions closed: 30
302% more capital invested
Capital invested by funds: $339M → $1.36B (+$1.02B)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
127% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 60
43% more call options, than puts
Call options by funds: $165M | Put options by funds: $115M
40% more funds holding
Funds holding: 276 → 386 (+110)
0.18% more ownership
Funds ownership: 17.2% → 17.38% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$86.1M |
| 2 |
HF
HRT Financial
New York
|
+$26.9M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$20M |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$10.2M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$92.6M |
| 2 |
AC
AlphaCore Capital
La Jolla,
California
|
-$20.4M |
| 3 |
Goldman Sachs
New York
|
-$20M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.9M |
| 5 |
Morgan Stanley
New York
|
-$7.44M |
IBRX Hedge Fund Activity: Q1 2026 in Review
386 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2026, worth a combined $1.36B — up 302% from $339M a quarter earlier.
Buyers outnumbered sellers: 145 funds opened new IBRX positions and 30 closed out — a net gain of 115 holders — while 136 added to existing stakes and 60 trimmed.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $86.1M. The largest seller was Jane Street, cutting an estimated $92.6M.
- 386 institutional investors held ImmunityBio (IBRX) as of Q1 2026, up from 276 in Q4 2025.
- Funds reported $1.36B of ImmunityBio stock for Q1 2026, up 302% quarter-over-quarter.
- 145 funds opened new ImmunityBio positions in Q1 2026 and 30 closed out, a net change of +115 holders.
- The largest ImmunityBio buyer in Q1 2026 was D.E. Shaw & Co, an estimated $86.1M added.
- The largest ImmunityBio seller in Q1 2026 was Jane Street, an estimated $92.6M sold.
Based on aggregated 13F filings for Q1 2026.